瑞格列奈联合二甲双胍治疗初发2型肥胖型糖尿病的临床研究

The Clinical Study of Repaglinide Combined with Metformin in Treatment with Obesity Type 2 Diabetes

目的观察瑞格列奈联合二甲双胍治疗初发2型肥胖型糖尿病的临床疗效。方法选取96例肥胖2型糖尿病患者随机分为两组,对照组48例采用二甲双胍治疗,观察组48例在对照组基础上采用瑞格列奈治疗,比较观察两组的血糖、血脂水平和体质量指数(BMI)的变化。结果两组治疗后FPG、2hPG水平均明显下降(P<0.05);并且,观察组治疗后FPG、2hPG水平均低于同期对照组水平(P<0.05)。与治疗前比较,观察组治疗后VLDL、TG及BMI水平明显下降(P<0.05),而对照组无明显差异(P>0.05)。并且,观察组治疗后VLDL、TG及BMI水平均明显低于同期对照组(P<0.05)。结论瑞格列奈联合二甲双胍初发2型肥胖型糖尿病进行治疗,降糖效果显著,并且能够明显降低患者血脂水平,值得临床推广应用。

ObjectiveTo observe the clinical effect of repaglinide combined with metformin in treatment with obesity type 2 diabetes.Method 96 cases of obesity type 2 diabetes patients were classified into two groups,which control group of 48 cases were treated with metformin and observation group of 48 cases were treated with repaglinide at the base of control group. The levels of blood sugar,blood fat and body mass index （BMI）between the two groups were compared.Results Compared with pre-treatment, the FPG, 2hPGwere significantly increased（P〈0.05）in both two groups after treatment. Moreover,the levels of FPG, 2hPG in observation group were significantly lower than those in control group（P〈0.05）.After treatment, the levels of VLDL,TG and BMI were significantly decreased,while no significant difference in control group（P〉0.05）. Moreover, the levels of VLDL, TG and BMI in observation group were significantly lower than those in control group（P〈0.05）.Conclusion Repaglinide combined with metformin in treatment with obesity type 2 diabetes can decrease blood sugar and blood fat,which can be applied in clinic.